1Gao R. et al. Human infection with a novel avian - origin influenza A (HTN9) virus. New England Journal of Medi- cine, 2013, 368(20) :1888 - 1897.
2Uyeki TM, Cox NJ. Global concerns regarding novel influ- enza A (H7N9) virus infections. New England Journal of Medicine, 2013, 368(20) :1862 - 1864.
3Hansen E, Day T, Arino J. et al. Strategies for the use of oseltamivir and zanamivir during pandemic outbreaks. Ca- nadian journal of infectious diseases and medical microbiol- ogy, 2010, 21(1) :28 -63.
4Hu Y. et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding amt emergence of antiviral re- sistaJme. Lancet. 2013,381 (9885) :2273 - 2279.
5Samson M, Pizzomo A, Abed Y. el al. lniiuenza ~'irus re- sistance to neuraminidase inhibitocs. ,kntiviral tteseareh, 2013, 98(2) :174 - 185.
6Whitley R J, Boueher CA, Lina B. el al. Global as:-~essment of resistance to neuraminidase inhibit(,rs: 2008 -2011. The intluenza resistance information stady (IRIS). Clini- cal infectious diseases, 2013, 56(9 ) , 1197 - 1205.
7Zekun Liu, Junpeng Zhao, Weieheo l,i. e~ al. Molectdar Docking of Potential Inhibitors tbr lnflue~ml I!7N9. Com- putational and Mathematical Methods in Medici~te, 2015,480764.
8Woods CJ, Malaisree M, I.ong B. et al. (~ompu',ational Assay of H7N9 Influenza Neuramlnida+e t+leveats it292 K Mutation Reduces Drug Binding ~kffinity. Scientific r~- ports, 2013,3:3561.
9Smoot ME, ()no K, Ruschemski J. ~1 a|. Cy~~scape 2.8: new featul~s for data integrati~n and net~.~o~k ~isualiza- tion. Bioinfonnatics (Oxford, England ) 2011 , 27:431 - 432.
